NCT06682793 - A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression | Biotech Hunter

Enrollment

240

Participants

Timeline

Start Date

May 22, 2025

Primary Completion Date

March 31, 2029

Study Completion Date

March 31, 2030

Conditions

Solid Tumor, AdultColorectal CancerNon-Small Cell LungNSCLC (Non-small Cell Lung Cancer)CancerColon CancerRectal CancerLung CancerCRCHead and Neck Squamous Cell CancerHNSCCRenal Cell CarcinomaRCCKidney CancerTriple Negative Breast CancerTNBCColorectal Adenocarcinoma

Interventions

BIOLOGICAL

A2B395

Allogeneic logic-gated Tmod CAR T cells

DIAGNOSTIC_TEST

xT CDx with HLA-LOH assay

An investigational next generation sequencing (NGS) in vitro diagnostic (IVD) medical device

Trial Locations (10)

10016

RECRUITING

NYU Langone Health, New York

32224

RECRUITING

Mayo Clinic, Jacksonville

33606

RECRUITING

Moffitt Cancer Center, Tampa

43210

RECRUITING

The Ohio State University, Columbus

55905

RECRUITING

Mayo Clinic, Rochester

63110

RECRUITING

Washington University, St Louis

85234

RECRUITING

Banner MD Anderson Cancer Center, Gilbert

90404

RECRUITING

UCLA Medical Center, Los Angeles

92093

RECRUITING

UCSD Moores Cancer Center, La Jolla

98109

RECRUITING

Fred Hutch Cancer Center, Seattle